36 Varieties Pass Consistency Evaluation: Qilu Pharmaceutical, Shijiazhuang Siyao, Jiudian Pharma Among Key Players
Qilu Pharmaceutical
Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer
Shijiazhuang No.4 Pharmaceutical Co.,Ltd.
Manufacturers and Service Providers of Chemical Drugs and Traditional Chinese Medicine
According to the NMPA official website, the drug approval certificates delivery information released on September 2, 2024, 36 varieties(60 Specifications)Passed/Deemed to have passed the consistency evaluation, involvingQilu Pharmaceutical, Shijiazhuang No.4 Pharmaceutical Co.,Ltd., JIUDIAN PHARMACEUTICALAnd many other pharmaceutical companies.
In this approval, from the perspective of the varieties that have passed the evaluation, there areDiquafosol Sodium Eye Drops, Famotidine Injection, Minoxidil Lotion, Nicorandil Tablets, Ambroxol Hydrochloride Oral Solution, Amiodarone Hydrochloride Injection, Indobufen Tablets, Cefazolin Sodium for Injection8 varietiesTwo pharmaceutical companies passed the evaluation on the same day.Procaterol Hydrochloride Oral SolutionThree pharmaceutical companies gain approval on the same day.
In this review of dosage forms, tablets accounted for the highest proportion, reaching 29.7%, followed by injections, with a proportion of 25.5%.In addition,Aminophylline Tablets, Sodium Valproate Sustained-Release Tablets (I)2 varietiesFirst to pass the evaluation.More details on the evaluation results can be found in the table below and the mini-program.
September 2nd Approved Varieties (Marked in Red for the First Approval)
END
Reply to the keyword "Report", access dozens of exclusive reports produced by Yaorongyun
Reply to the keyword "First Generic in 2023", Obtain the list of first generic drugs approved in 2023
AfterPlatform Reply"GLP-1 In-depth Report", to obtain the complete "GLP-1 Industry Status and Future Development" PDF version.
Reply in the background"China Class I New Drug", Obtain the complete"China Class I New Drug Targets" PDF Version.
Reply in the background“NAFLD/NASH”，Get the full PDF version of the "NAFLD/NASH Report".
Reply in the background"AI + Pharmaceutical", get complete"White Paper on China's AI Pharmaceutical Enterprises"PDF Version.
Reply in the background“XXG”, get complete"Analysis Report on Cardiovascular System Drugs in China"PDF Version.
Reply in the background“FZZJ”, get complete"Analysis of Complex Injectable Formulations Based on Dosage Form Improvement"PDF Version.
Background Reply"Import and Export of Pharmaceuticals", get complete"White Paper on China's Import and Export of Pharmaceuticals"In-depth Report - PDF Version.
Contact us to experience more professional services from PharmaCloud. | ||||
MeetingDiscussion CombineAuthor | GardenDistrict TakeService | Database Consultation | Customized Service | Media Cooperation |
